FDA Cites J&J Duragesic Promotion For Misleading Safety Profile
This article was originally published in The Pink Sheet Daily
Executive Summary
Reports from a national drug abuse surveillance database are not sufficient basis for comparative safety claims between the Duragesic patch and other pain agents, FDA says. The agency asks J&J to devise a corrective action plan for a violative professional file card that was distributed beginning in 2003.
You may also be interested in...
FDA Drug Ad Warning Letters Total Four In September; J&J Cited Three Times
FDA's drug ad division posted four warning letters to its website in the second half of September, three for Johnson & Johnson ads
FDA Drug Ad Warning Letters Total Four In September; J&J Cited Three Times
FDA's drug ad division posted four warning letters to its website in the second half of September, three for Johnson & Johnson ads
J&J Duragesic Shortage Resolved
Short supply issues for Janssen's opioid analgesic transdermal patch are resolved. The company recalled lots of Duragesic in February and April due to possible medication leakage along one edge.